EQ Average Annual Return 10 Years
EQ Average Annual Return Chart Since 2018
Growth of $10,000.00
Without Dividends Reinvested Into EQ

Also see:
• EQ stock yearly return 2018
• EQ stock yearly return 2019
• EQ stock yearly return 2020
• EQ stock yearly return 2021
• EQ stock yearly return 2022
• EQ stock yearly return 2023
• EQ stock yearly return 2024
• EQ stock yearly return 2025
• EQ YTD return
Average Annual Return Benchmarks
Compare EQ average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
EQ Share Performance
EQ Average Annual Return Table Since 2018
Start date: 10/15/2018
End date: 04/17/2026
Start price/share: $14.00
End price/share: $2.05
Dividends collected/share: $0.00
Total return: -85.36%
EQ Average Annual Return: -22.57%
Starting investment: $10,000.00
Ending investment: $1,464.72
Years: 7.51


EQ average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About Equillium Inc
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Co.'s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Co.'s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. The EQ average annual return since 2018 is shown above.

The Average Annual Return on the EQ average annual return since 2018 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether EQ average annual return since 2018 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the EQ average annual return calculation with any dividends reinvested as applicable (on ex-dates).
EQ Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree EQ Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!
Average Annual Return Peers
Equillium (EQ) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

ERAS Average Annual Return
ERNA Average Annual Return
ESPR Average Annual Return
ETON Average Annual Return
EVFM Average Annual Return
EW Average Annual Return
EWTX Average Annual Return
EXEL Average Annual Return
EYE Average Annual Return
EYEG Average Annual Return
More Healthcare companies »
 

EQ Average Annual Return 10 Years | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.